F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
Everett E. Vokes,Neal Ready,Enriqueta Felip,Leora Horn,Marco Angelo Burgio,S.J. Antonia,O. Aren Frontera,Scott N. Gettinger,Esther Holgado,David R. Spigel,David M. Waterhouse,Manuel Domine,Marina Chiara Garassino,Laura Q.M. Chow,George R. Blumenschein,Fabrice Barlesi,Bruno Coudert,Justin F. Gainor,Oscar Arrieta,Julie R. Brahmer,Charles Butts,Martin Steins,William J. Geese,Ang Li,Diane Healey,L. Crinò +25 more
TL;DR: In this article, the anti-programmed death-1 antibody nivolumab versus docetaxel was compared in patients with previously treated advanced squamous (CheckMate 017) and nonsquamous NSCLC.
Journal ArticleDOI
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Corinne Faivre-Finn,Michael Snee,Linda Ashcroft,W. Appel,Fabrice Barlesi,Adityanarayan Bhatnagar,Andrea Bezjak,Felipe Cardenal,Pierre Fournel,Susan Harden,Cécile Le Péchoux,Rhona McMenemin,Nazia Mohammed,Mary O'Brien,Jason Pantarotto,Veerle Surmont,Jan P. van Meerbeeck,Penella J. Woll,Paul Lorigan,Fiona H Blackhall +19 more
TL;DR: Survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and lower than expected with both regimens.
Journal ArticleDOI
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity
Marion Escudier,Jennifer Cautela,N. Malissen,Yann Ancedy,Morgane Orabona,Johan Pinto,Sandrine Monestier,Jean-Jacques Grob,Ugo Scemama,Alexis Jacquier,Nathalie Lalevée,Jeremie Barraud,Michael Peyrol,Marc Laine,Laurent Bonello,Franck Paganelli,Ariel Cohen,Fabrice Barlesi,Stéphane Ederhy,Franck Thuny +19 more
TL;DR: The medical records of patients with a clinical suspicion of ICI-related cardiotoxicity were reviewed from the databases of 2 cardio-oncology units between March 2015 and April 2017 and found no specific follow-up had previously been established for patients receiving ICIs during the study period.
Journal ArticleDOI
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Fabrice Barlesi,Johan Vansteenkiste,David R. Spigel,Hidenobu Ishii,Marina Chiara Garassino,Filippo de Marinis,Mustafa Ozguroglu,Aleksandra Szczesna,Andreas Polychronis,Ruchan Uslu,Maciej Krzakowski,Jong Seok Lee,Luana Calabrò,Osvaldo Arén Frontera,Barbara Ellers-Lenz,Marcis Bajars,M. Ruisi,Keunchil Park +17 more
TL;DR: This trial investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy and found median overall survival did not differ significantly between the aVELumab and docetaxel groups.
Journal ArticleDOI
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard,Tae Min Kim,Julien Mazieres,Elisabeth Quoix,Gregory J. Riely,Gregory J. Riely,Fabrice Barlesi,Pierre Jean Souquet,Egbert F. Smit,Harry J.M. Groen,Harry J.M. Groen,Ronan J. Kelly,Byoung Chul Cho,Mark A. Socinski,Lini Pandite,Christine Nase,Bo Ma,Anthony D'Amelio,Bijoyesh Mookerjee,C. Martin Curtis,Bruce E. Johnson +20 more
TL;DR: Dabrafenib showed clinical activity in BRAF(V600E)-positive NSCLC and could represent a treatment option for a population of patients with limited therapeutic options.